Osteolytic lesions occur rarely in patients with B-CLL and may respond well to ibrutinib

Evgenii ShumilovDepartment of Haematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany;

Gerald WulfDepartment of Haematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany;

Philipp StröbelDepartment of Pathology, University Medicine Goettingen, Goettingen, Germany;

Justin HasenkampDepartment of Haematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany;

Niels HelligeDepartment of Diagnostic and Interventional Radiology, University Medicine Goettingen, Goettingen, Germany;

Annalen BleckmannDepartment of Haematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany;

Detlef HaaseDepartment of Haematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany;

Friederike BraulkeDepartment of Haematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany;

Wolfram JungDepartment of Haematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany;

Julie SchanzDepartment of Haematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany;

Mascha BinderDepartment of Oncology and Haematology, University Cancer Center Hamburg (UCCH), Hamburg, Germany

Lorenz TrümperDepartment of Haematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany;

Ulrike BacherDepartment of Haematology and Medical Oncology, University Medicine Goettingen, Goettingen, Germany; Correspondence[email protected]

Your download is now in progress and you may close this window